Article info
PDFExtended report
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate
- Correspondence to:
Dr J Gratacós
Rheumatology Unit, Parc Taulí University Hospital, Parc Taulí s/n. 08208 Sabadell, Barcelona, Spain; jgratacos{at}cspt.es
Citation
Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate
Publication history
- Accepted December 2, 2006
- First published December 19, 2006.
Online issue publication
April 15, 2023
Article Versions
- Previous version (25 October 2017).
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2007 by Annals of the Rheumatic Diseases